Welcome to our dedicated page for Atricure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtriCure, Inc. filings document financial results, governance matters and capital arrangements for a Nasdaq-listed medical technology company focused on Afib, left atrial appendage management and post-operative pain management. Form 8-K reports furnish quarterly and annual results, amended financial guidance disclosures, product-revenue drivers and material definitive agreements, including an asset-based revolving credit facility involving AtriCure, LLC as a borrower.
Proxy filings cover board and shareholder voting matters, executive compensation, equity awards and related governance disclosures. The filings also identify AtriCure common stock as registered on the Nasdaq Global Market under the symbol ATRC.
AtriCure, Inc. director Karen Prange reported an open-market sale of 3,000 shares of common stock on May 20, 2026 at a weighted average price of $28.65 per share. After this transaction, she directly holds 26,373 shares of AtriCure common stock.
The sale was executed in multiple trades within a price range of $28.60 to $28.76 per share, with the reported price reflecting the weighted average sales price.
AtriCure, Inc. director Karen Prange reported an equity compensation grant of common stock. She acquired 6,144 shares of AtriCure common stock at no cash cost as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan, which will vest on the one-year anniversary of the grant date. Following this award, she holds 29,373 common shares directly.
Telman Deborah H reported acquisition or exercise transactions in this Form 4 filing.
AtriCure, Inc. director Deborah H. Telman received a grant of 6,144 shares of Common Stock as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest on the one-year anniversary of the grant date. Following this award, she holds 28,328 shares of AtriCure common stock directly.
AtriCure, Inc. director Maggie Yuen reported receiving a grant of common stock as equity compensation. She was awarded 6,144 shares of Common Stock on May 18, 2026 at a stated price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan.
The award is structured as restricted stock and will vest on the one-year anniversary of the grant date. Following this grant, Yuen directly holds 17,515 shares of AtriCure common stock. This filing reflects a compensation-related acquisition rather than an open-market purchase.
Nachman Shlomo reported acquisition or exercise transactions in this Form 4 filing.
AtriCure director Nachman Shlomo received a grant of 6,144 shares of AtriCure, Inc. common stock as a Restricted Stock Award under the company’s 2023 Stock Incentive Plan. The award was granted at no cash cost and will fully vest on the one-year anniversary of the grant date. Following this equity grant, Shlomo directly owns 24,655 shares of AtriCure common stock.
AtriCure, Inc. director Kristine B. Johnson reported receiving a grant of common stock as equity compensation. She acquired 6,144 shares of Common Stock on May 18, 2026 at a stated price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan.
The award is structured as a Restricted Stock Award, with all 6,144 shares scheduled to vest on the one-year anniversary of the grant date. Following this grant, Johnson directly holds a total of 55,954 shares of AtriCure common stock, reflecting her updated ownership position as reported.
GROVES REGINA E reported acquisition or exercise transactions in this Form 4 filing.
AtriCure, Inc. director Regina E. Groves received a grant of 6,144 shares of Common Stock as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The footnote states these shares will vest on the one-year anniversary of the grant date. After this equity award, Groves directly holds 39,859 shares of AtriCure common stock.
WEHRWEIN SVEN reported acquisition or exercise transactions in this Form 4 filing.
AtriCure, Inc. director Sven Wehrwein received a grant of 6,144 shares of common stock as equity compensation. The award was made at a price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan and is structured as a Restricted Stock Award. According to the terms, these shares will vest on the one-year anniversary of the grant date. Following this grant, Wehrwein directly holds a total of 40,518 shares of AtriCure common stock.
WHITE ROBERT S. reported acquisition or exercise transactions in this Form 4 filing.
AtriCure, Inc. director Robert S. White received a grant of 6,144 shares of common stock as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award has no purchase price and will vest in full on the one-year anniversary of the grant date.
After this grant, White directly holds a total of 128,318 shares of AtriCure common stock, reflecting routine equity-based compensation rather than an open-market purchase or sale.